Further, in a recent, small study of JIA patients by Levalampi and colleagues, treatment with infliximab resulted in reductions in levels of C-reactive protein (CRP), adhesion molecules (ICAM-1, E -selectin) and myeloperoxidase [14]. The gene discussed is ICAM1; the disease is juvenile idiopathic arthritis.